Evidence map›Paper›PMID 31681861›Full record

ArticleInternational journal of ophthalmic research2018

Advances in Retinal Laser Therapy.

Jia Li, Yannis Mantas Paulus

Open access · diamondAbstract read
In one paragraph

Article in International journal of ophthalmic research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edema.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Jia LiDepartment of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yannis Mantas PaulusDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Jiangsu Province Hospital · CNUniversity of Michigan–Ann Arbor · US

Funding

Michigan Vision Clinician Scientist Development ProgramK12EY022299 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Abigail Fahim, DAVID N ZACKS · 2013 to 2026
$6.3M
NEI NIH HHS K12 EY022299
6 · The paper itself

Abstract

Since the 1960s, laser therapies have played a critical role in the treatment of numerous retinal diseases. Significant advances have been made in laser technology and the molecular understanding of laser-tissue interactions over the past 55 years to maximize the therapeutic effect while minimizing side-effects. While pharmacologic therapies (e.g., anti-vascular endothelial growth factor or anti-VEGF) are playing a larger role, laser therapy remains an important treatment modality for proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), sickle cell retinopathy, retinal vein occlusions, central serous chorioretinopathy, tumors, polypoidal choroidal vasculopathy, and retinal tears. With the development new laser technologies such as selective retinal therapy, subthreshold micropulse laser, nanosecond laser, photomediated ultrasound therapy, and navigated laser, the risk of adverse events has been significantly reduced. This review summarizes the latest developments in retinal laser therapy.

Indexed as

Laser photocoagulationNanosecond pulse laserNavigated laserPhoto-mediated ultrasound therapyRetinaSelective retinal therapySubthreshold micropulse laser

Identifiers

PMID31681861
PMCPMC6824197
OpenAlexW2795824457

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.